decemb
sever
patient
unexplain
pneumonia
appear
wuhan
china
viral
pneumonia
sweep
world
process
gestat
sever
day
later
viru
identifi
new
beta
coronaviru
offici
name
sever
acut
respiratori
syndrom
coronaviru
march
diseas
caus
infect
china
case
fatal
rate
total
confirm
case
report
countri
world
mortal
rate
much
differ
china
although
patient
present
mild
symptom
lifethreaten
number
death
still
high
due
larg
popul
base
first
patholog
found
bilater
diffus
alveolar
injuri
cytomyxoid
fibroma
exud
subsequ
peripher
flow
cytometri
analysi
found
decreas
cell
increas
cell
proport
studi
publish
jing
liu
et
al
incorpor
patient
sever
suggest
sever
case
show
sustain
decreas
proport
lymphocyt
compar
mild
case
addit
cell
decreas
inflammatori
cytokin
increas
sever
case
peripher
blood
take
togeth
reason
hypothesi
cytokin
storm
play
import
role
sever
case
neutral
key
inflammatori
factor
cr
great
valu
reduc
mortal
sever
case
cr
system
inflammatori
respons
caus
infect
drug
factor
character
sharp
increas
level
larg
number
proinflammatori
cytokin
cr
common
immun
systemrel
diseas
immunerel
therapi
cart
cell
therapi
organ
transplant
sepsi
viru
infect
bind
alveolar
epitheli
cell
viru
activ
innat
immun
system
adapt
immun
system
result
releas
larg
number
cytokin
includ
addit
due
role
proinflammatori
factor
vascular
permeabl
increas
larg
number
fluid
blood
cell
alveoli
result
dyspnea
even
respiratori
failur
figur
first
gross
examin
report
death
autopsi
suggest
bronz
appear
lung
larg
amount
graywhit
viscou
liquid
overflow
seen
incis
import
member
cytokin
network
play
central
role
acut
inflamm
discov
weissenbach
multifunct
cytokin
play
import
role
human
metabol
autoimmun
cell
differenti
diseas
treatment
brief
introduct
shown
figur
small
polypeptid
consist
four
alpha
helic
molecular
weight
amino
acid
residu
usual
monom
form
isoelectr
point
glycosyl
site
two
disulfid
bond
gene
encod
locat
chromosom
includ
intron
exon
produc
almost
stromal
cell
immun
system
cell
b
lymphocyt
lymphocyt
macrophag
monocyt
dendrit
cell
mast
cell
nonlymphocyt
fibroblast
endotheli
cell
keratinocyt
glomerular
mesangi
cell
tumor
cell
main
activ
express
tumor
necrosi
factor
cours
way
promot
synthesi
tolllik
receptor
prostaglandin
adipokin
stress
respons
cytokin
earli
stage
infecti
inflamm
produc
monocyt
macrophag
stimul
tolllik
receptor
noninfecti
inflamm
burn
traumat
injuri
also
produc
cell
stimul
tolllik
receptor
acut
express
play
central
role
host
defens
stimul
variou
cell
popul
play
central
role
cytokin
storm
multieffect
cytokin
antiinflammatori
proinflammatori
effect
three
main
pathway
signal
transduct
classic
signal
transduct
pathway
bind
receptor
form
complex
bind
membran
protein
initi
intracellular
signal
transduct
exist
transmembran
form
also
solubl
form
bind
two
form
interact
trigger
downstream
signal
transduct
gene
express
tran
signal
transduct
pathway
bind
affin
similar
complex
bind
initi
intracellular
signal
transduct
classic
signal
pathway
mani
cell
respond
signal
express
cell
stimul
complex
respond
signal
caus
cell
signal
transduct
tran
present
signal
suppress
extracellular
form
complex
prevent
bind
membranebound
promot
cell
popul
expans
activ
b
cell
differenti
regul
acut
phase
respons
affect
hormonelik
properti
vascular
diseas
lipid
metabol
insulin
resist
mitochondri
activ
neuroendocrin
system
neuropsycholog
behavior
addit
promot
differenti
osteoclast
angiogenesi
prolifer
keratinocyt
glomerular
membran
cell
growth
myeloma
plasmacytoma
cell
classic
signal
limit
cell
macrophag
neutrophil
cell
etc
express
play
lead
role
low
level
combin
cellrel
lead
homolog
dimer
initi
downstream
pathway
howev
level
increas
signal
wide
express
everywher
bind
tocilizumab
cellrel
solubl
inhibit
classic
tran
signal
inhibit
cr
tocilizumab
recombin
human
monoclon
antibodi
human
interleukin
receptor
immunoglobulin
subtyp
tocilizumab
specif
bind
solubl
membranebound
receptor
inhibit
signal
transduct
approv
treatment
rheumatoid
arthriti
system
juvenil
idiopath
arthriti
addit
also
report
play
certain
role
castleman
diseas
crohn
diseas
worth
note
tocilizumab
effect
treatment
sever
cr
patient
recommend
dose
tocilizumab
kg
intraven
drip
everi
week
adult
rheumatoid
arthriti
use
combin
methotrex
antirheumat
drug
liver
enzym
abnorm
neutrophil
count
platelet
count
decreas
dose
tocilizumab
reduc
system
juvenil
idiopath
arthriti
sjia
patient
dose
tocilizumab
bodi
weight
bodi
intraven
drip
everi
week
recommend
drip
time
hour
safeti
tocilizumab
iii
phase
doubleblind
control
trial
extend
period
studi
data
come
treatment
rheumatoid
arthriti
total
control
popul
includ
patient
doubleblind
period
core
studi
random
group
first
chang
treatment
regimen
complet
treatment
period
among
doubleblind
control
period
studi
month
doubleblind
control
period
year
doubleblind
control
trial
patient
receiv
tocilizumab
combin
mtx
methotrex
patient
tocilizumab
combin
mtx
dmard
diseasemodifi
antirheumat
drug
total
patient
treat
tocilizumab
alon
control
trial
incid
infect
event
patient
tocilizumab
dmard
placebo
dmard
patientyear
patientyear
respect
among
total
expos
popul
overal
incid
infect
event
tocilizumab
dmard
group
case
patient
year
control
trial
also
show
incid
sever
infect
bacteria
virus
fungi
dmard
group
patientyear
placebo
dmard
group
monotherapi
trial
incid
sever
infect
patientyear
tocilizumab
group
patientyear
mtx
group
regard
safeti
tocilizumab
treatment
patient
sever
preprint
studi
includ
studi
patient
mean
age
year
rang
year
complic
associ
tocilizumab
histori
ill
deterior
death
overal
risk
secondari
infect
tocilizumab
high
show
confirm
case
includ
hypertens
among
case
die
crude
death
rate
unreport
complic
mortal
rate
patient
complic
much
higher
patient
cardiovascular
diseas
patient
diabet
patient
hypertens
controversi
whether
tocilizumab
increas
risk
cardiovascular
diseas
cvd
data
sever
random
control
trial
rct
realworld
evid
rwe
studi
publish
gile
jt
et
al
studi
includ
patient
year
old
one
cvd
risk
factor
cardiovascular
diseas
met
diagnosi
activ
therapi
girl
acut
lymphoblast
leukemia
develop
sever
cytokin
storm
cart
treatment
subsequ
treatment
tocilizumab
dramat
improv
condit
affect
efficaci
cart
anoth
report
report
male
patient
develop
hemophagocyt
lymphohistiocytosi
hlh
treatment
blinatumomab
patient
develop
sever
respiratori
failur
methemoglobinemia
subsequ
treatment
tocilizumab
success
save
patient
life
sar
mer
coronavirus
cr
vari
degre
occur
sever
patient
sar
mer
high
express
current
small
sampl
clinic
trial
china
clinic
trial
registr
id
shown
good
efficaci
tocilizumab
patient
group
met
criteria
sever
critic
among
sever
criteria
meet
one
follow
short
breath
respiratori
rate
beat
min
oxygen
satur
less
rest
mmhg
critic
criteria
meet
one
follow
respiratori
failur
requir
mechan
ventil
shock
admiss
icu
organ
failur
day
treatment
fever
patient
bodi
temperatur
return
normal
begin
patient
fever
symptom
significantli
improv
patient
reduc
oxygen
intak
one
patient
need
oxygen
imag
examin
ct
scan
show
patient
absorpt
pulmonari
lesion
laboratori
examin
show
proport
peripher
blood
lymphocyt
creactiv
protein
return
normal
defici
level
peripher
blood
treatment
tocilizumab
report
mean
valu
pgml
level
treatment
report
final
although
analysi
possibl
mechan
small
sampl
clinic
data
tocilizumab
better
efficaci
howev
point
view
pharmacoeconom
suggest
use
critic
ill
patient
significantli
elev
conclus
cr
occur
larg
number
patient
sever
also
import
caus
death
key
molecul
cr
antagonist
tocilizumab
may
import
drug
save
patient
live
